Valneva announces expansion of its commercial operation in France

Valneva SE, a commercial stage biotech company, has reportedly announced its plan to expand its commercial infrastructure in France with the opening of a new commercial office in Lyon, France.

Valneva France, SAS, a commercial subsidiary, would now take control of marketing and sales of DUKORAL® and IXIARO® in France with the goal of stimulating sales growth of these vaccines.  

Franck Grimaud, CBO, Valneva, stated that since recovering the global distribution rights of their Japanese encephalitis vaccine back 2015, the company has continued to extend its commercial infrastructure across major travel markets. This has allowed the company to double its sales from 2015.

Grimaud further stated that based on the experience the company has gathered and by providing focus through a committed team of sales and marketing, Valneva expects to increase the sales and market penetration in France.

Recently, the company reportedly also announced the End of Phase 2 meeting, that is to be scheduled on February 24, 2020 with the U.S. FDA (Food and Drug Administration) for its chikungunya vaccine candidate, that is VLA1553.

The company is further planning for Phase 3 clinical studies as well as licensure. The Chikungunya vaccine candidate might be eligible for a priority review voucher and has been allocated designation of Fast Track by the FDA.

Valneva, reported the final Phase 1 results in November 2019 confirming VLA1553’s immunogenicity and safety profile. Furthermore, it has also completed non-clinical studies that were requested by the FDA.

According to reports, the financials related to the company’s France expansion have not been unveiled as of yet.

About Valneva SE:

Valneva, a renowned biotech firm developing and commercializing vaccines for infectious diseases with major unsatisfied needs. The company has an increasing commercial business along with two successful vaccines for travelers and various other clinical stage vaccines in development. It also has unique vaccine against chikungunya and Lyme disease. The company operates in UK, France, Canada, Sweden, Austria and the U.S employing nearly 490 individuals.

Source credit: https://valneva.com/press-release/valneva-expands-its-commercial-operations-with-the-opening-of-its-french-commercial-office/